AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera's long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera's breakthrough tunable hydrogel platform,...